Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.39 |
| ▸ | PDE1A | P54750 | 2/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28563034 | 1.00 | LRRK2 (0.39) | LRRK2FLT3MAP3K1PI4KBPDE1A | |
| SCHEMBL16985277 | 0.91 | JAK1 (0.39) | LRRK2FLT3MAP3K1PI4KBPDE1A | |
| SCHEMBL5021081 | 0.90 | LRRK2 (0.43) | LRRK2PDE1APDE1BPDE1CALOX15 | |
| SCHEMBL4561032 | 0.86 | LRRK2 (0.40) | LRRK2PDE1BPDE1CALOX15 | |
| SCHEMBL23275182 | 0.81 | ALOX15 (0.47) | LRRK2PDE1APDE1BPDE1CALOX15 | |
| SCHEMBL23284456 | 0.81 | PIK3CA (0.39) | LRRK2FLT3MAP3K1PI4KBPDE1A | |
| SCHEMBL5021135 | 0.80 | LRRK2 (0.47) | LRRK2ALOX15MAP3K12 | |
| SCHEMBL16985378 | 0.80 | LRRK2 (0.36) | LRRK2FLT3MAP3K1PI4KBALOX15 | |
| SCHEMBL16975518 | 0.79 | LRRK2 (0.49) | LRRK2ALOX15 | |
| SCHEMBL17076787 | 0.78 | LRRK2 (0.41) | LRRK2ALOX15MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112771032-B | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors | 江苏先声药业有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-112771032-A | Pyrimidine pyrazole compounds as fourth generation EGFR inhibitors | 江苏先声药业有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3590933-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| EP-2638031-B9 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2020-01-08 | — | — | EP | disclosed |
| EP-2638031-B9 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2020-01-08 | — | — | EP | disclosed |
| EP-3124483-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3124483-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | LRRK2 1/4885FLT3 4319/4885MAP3K1 57/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885FLT3 504/4885MAP3K1 69/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885FLT3 310/4885MAP3K1 71/4885 |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885FLT3 1075/4885MAP3K1 194/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | LRRK2 1/4885FLT3 4372/4885MAP3K1 49/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LRRK2 1/4885FLT3 407/4885MAP3K1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.